InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $12.790 -5.06 (-28.35%)+
Announcement
Release
21 Sep 2026 8:38AM
Price at Release
$17.850
Full Release
download
Summary
The presentation dated 21 September 2026 outlines Telix Pharmaceuticals Limited’s proposed acquisition of ITM Isotope Technologies Munich SE to create a vertically integrated radiopharmaceutical company with expanded isotope manufacturing, therapeutics and precision medicine capabilities. Telix proposes to acquire 100% of ITM for US$1.65 billion upfront on a cash-free/debt-free basis, with up to a further US$700 million in contingent milestone and sales-based consideration, and expects ITM shareholders to own 23.7% of Telix at closing, which is targeted by the end of FY2026 subject to shareholder and regulatory approvals. Strategically, the transaction adds ITM’s commercial-scale lutetium-177 manufacturing platform, global distribution network across 65 countries, expansion potential into actinium-225 and terbium-161, and a late-stage therapeutic asset, ITM-11, for gastroenteropancreatic neuroendocrine tumours. The document highlights ITM-11’s positive Phase 3 COMPETE data showing improved progression-free survival versus everolimus, ongoing expansion studies in higher-grade GEP-NETs and lung NETs, and notes that an FDA complete response letter received on 7 August 2026 was limited to CMC and third-party facility issues, with no clinical or nonclinical deficiencies identified. Financially, the combination is presented as enhancing Telix’s scale and business mix, with pro forma 2025 revenue of US$1.077 billion, estimated 2026 combined revenue and other income of about US$1.3 billion, pro forma cash of US$325 million as at 30 June 2026, and expected positive EBITDA contribution from ITM from FY2027 onward, alongside targeted synergies of US$50 million in the first two years, while the latter part of the presentation details transaction structure, governance, escrow arrangements, pro forma financial statements and extensive transaction, integration, regulatory, supply chain and operational risks.
Key Points
  • Telix announced a proposed acquisition of ITM to create a radiopharmaceutical powerhouse with enhanced capabilities across the value chain.
  • The presentation is dated 21 September 2026.
  • Telix proposes to acquire 100% of ITM for US$1.65 billion upfront plus up to US$700 million in contingent milestone and sales-based consideration.
  • ITM shareholders are expected to own 23.7% of Telix shares on issue at closing, subject to escrow restrictions.
  • Closing is targeted by the end of FY2026, subject to Telix shareholder approval, regulatory approvals and other customary conditions.
  • The deal is positioned as creating a differentiated, vertically integrated radiopharmaceutical company with manufacturing, therapeutics and commercial precision medicine capabilities.
  • ITM is described as the world’s largest supplier of commercial and clinical lutetium-177 by revenue.
  • ITM’s manufacturing platform spans raw materials, irradiation, GMP production, quality control release and logistics.
  • ITM distributes across 65 countries and more than 400 destinations weekly, with just-in-time delivery and a reported order fulfilment rate above 99% in 2025.
  • ITM is expanding beyond lutetium-177 into actinium-225 through the Actineer joint venture and has plans for terbium-161.
  • The combined supply chain is presented as covering a wide range of therapeutic and diagnostic isotopes including 68Ga, 89Zr, 18F, 211At, 153Sm and 212Pb.
  • ITM reported audited 2025 revenue of US$273 million and employed about 850 staff.
  • Historical ITM revenue is shown growing from US$70 million in 2021 to US$273 million in 2025, a roughly 40% CAGR.
  • The presentation cites forecast growth in the 177Lu and 225Ac markets through 2035.
  • A central therapeutic rationale is ITM-11, a novel SSTR-targeted radiopharmaceutical using edotreotide and n.c.a. 177Lu for GEP-NETs.
  • ITM-11 is presented as a potential entry point for Telix into the commercial therapeutic market, subject to regulatory approval.
  • The COMPETE Phase 3 trial met its primary endpoint, with median progression-free survival of 23.9 months for ITM-11 versus 14.1 months for everolimus.
  • Safety data in COMPETE showed a lower incidence of Grade 3/4 treatment-related adverse events for ITM-11 than for everolimus.
  • The presentation states COMPETE is the first Phase 3 head-to-head PRRT evidence versus standard of care in GEP-NETs.
  • Additional ITM-11 Phase 3 programs include COMPOSE for aggressive Grade 2/3 GEP-NETs and LEVEL for lung and thymic NETs.
  • The FDA issued a complete response letter for ITM-11 on 7 August 2026 limited to CMC and third-party facility inspection items.
  • The FDA complete response letter did not identify clinical safety or efficacy issues and did not request additional clinical or nonclinical data.
  • Resubmission of the ITM-11 NDA or an agreed path forward is identified as a closing condition for the transaction.
  • The transaction is expected to improve Telix’s growth strategy through vertical integration, pipeline expansion, commercial depth and enhanced R&D capability.
  • Pro forma combined revenue for 2025 is shown as US$1.077 billion, with estimated 2026 revenue and other income of about US$1.3 billion.
  • ITM is expected to contribute positively to group EBITDA from FY2027 onward.
  • Telix highlights targeted synergies of US$50 million in the first two years in addition to ITM cost savings.
  • Pro forma cash for the combined entity is shown as US$325 million as at 30 June 2026.
  • The presentation also includes detailed pro forma income statements, balance sheet information and extensive risk disclosures related to completion, integration, regulation, supply chain, operations and technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.